Kang et al synthesized and biologically evaluated a novel 18F-labeled 5-resorcinolic triazolone derivative (1, [18F] PTP-Ganetespib) based on Ganetespib, a most promising candidate among several HSP90 inhibitors under clinical trials, which entered “phase III” clinical trials for cancer therapy [199]. The gene discussed is HSP90AA1; the disease is cancer.